Oxford, UK; 18 January 2005 - Oxford Immunotec, the T cell diagnostics company, today announced that it has appointed Stuart Rose as Global Marketing Director.  Mr. Rose brings 20 years of marketing and sales experience in the international pharmaceutical industry, from blue chip to start-up.  

Most recently, Mr. Rose was Principal of pharmaSMART Consulting which developed market entry strategies across Europe and the US for biotech and biopharma companies. Prior to this he was Senior Director, International Brand Marketing at Elan, a researched based biopharmaceutical company.  Mr. Rose has served as Chair of the Healthcare Communications Association and as a judge for the Pharmaceutical Marketing Communiqué Awards.  

Commenting on the appointment, Dr Peter Wrighton-Smith, CEO of Oxford Immunotec, said, “We are very excited to have Stuart join the team.  His breadth of experience working in both leading pharmaceutical and entrepreneurial companies will be extremely valuable to our expansion efforts.  He shares our ambitious plans and the recruitment of such a senior-level marketer reflects our commitment to growth.” 

Earlier positions included sales at Roussel (now Sanofi-Aventis) plus domestic and international strategic brand management at Scotia, Novo Nordisk and Glaxo Wellcome (now GSK).  

ENDS 

Notes to Editors: 

Oxford Immunotec

www.oxfordimmunotec.com.

Oxford Immunotec, the T cell diagnostics company, is headquartered near Oxford, UK. The Company develops and sells clinical diagnostic products based on its patented T SPOT™ technology. T SPOT is a novel platform technology that opens up new ways of diagnosing and monitoring infections by providing a simple and extremely accurate method of studying a person’s cellular immune response to an infection. T-SPOT technology can be applied to diagnose and monitor any major disease driven by a T-cell response.

Oxford Immunotec's first product is T SPOT-TB, a revolutionary new in vitro diagnostic test for tuberculosis infection, recently approved for sale in Europe. It is designed to replace the tuberculin skin test for the diagnosis of TB infection. T SPOT-TB allows the reliable screening and early detection of TB infection and will bring TB testing to many new patient groups where the skin test gives poor or un-interpretable results. It offers a substantially more accurate and effective tool for controlling the spread of TB. T SPOT-TB addresses a market of £600m.